Published in Infection on May 26, 2009
Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol (2011) 1.43
Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol (2010) 1.33
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis (2012) 0.99
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther (2015) 0.97
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics (2014) 0.95
Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up. AIDS Patient Care STDS (2013) 0.87
Safety of protease inhibitors in HIV-infected pregnant women. HIV AIDS (Auckl) (2013) 0.85
Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to? Indian J Med Res (2011) 0.84
Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infect Dis (2016) 0.81
Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis (2015) 0.80
Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients. Indian J Pharmacol (2016) 0.75
Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study. AIDS Res Hum Retroviruses (2012) 0.75
Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients. AIDS Res Hum Retroviruses (2012) 0.75
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. BMC Infect Dis (2017) 0.75
Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation. Pharmacogenet Genomics (2017) 0.75
A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med (1995) 3.89
Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr (2001) 3.83
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology (1994) 3.05
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis (2001) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet (1995) 2.47
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst (1998) 2.32
Rhodococcus equi infection in HIV-infected patients. AIDS (1996) 2.32
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A (1994) 2.29
Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 2.24
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Transmission of HIV-associated tuberculosis to health-care workers. Lancet (1992) 2.23
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol (1998) 2.21
A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med (1991) 2.10
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res (1997) 2.05
AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology (2000) 2.05
Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS (2000) 1.91
Mother-to-child transmission of hepatitis C virus detected by nested polymerase chain reaction. J Infect Dis (1992) 1.90
Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. Ann Neurol (1991) 1.84
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis (2001) 1.84
Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia. Lancet (1992) 1.81
Determinants of survival in progressive multifocal leukoencephalopathy. Neurology (2009) 1.77
Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2000) 1.73
Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med (1994) 1.72
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS (1998) 1.70
Sternal wound infections and use of internal mammary artery grafts. J Thorac Cardiovasc Surg (1991) 1.69
Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet (1993) 1.68
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer (2003) 1.67
Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.66
Brief report: disseminated mycobacteriosis caused by drug-resistant Mycobacterium triplex in a human immunodeficiency virus-infected patient during highly active antiretroviral therapy. Clin Infect Dis (2000) 1.65
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology (2011) 1.65
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med (2011) 1.64
The magnetic field of an isolated neutron star from X-ray cyclotron absorption lines. Nature (2003) 1.63
Racial differences in performance of invasive cardiac procedures in a Department of Veterans Affairs Medical Center. J Clin Epidemiol (1997) 1.59
The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets (2005) 1.59
Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. Clin Exp Immunol (1985) 1.57
How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group (ISS) J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.57
Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS (1997) 1.57
Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet (1991) 1.56
Application of molecular methods for detection and transmission analysis of mycobacterium tuberculosis drug resistance in patients attending a reference hospital in Italy. J Infect Dis (1999) 1.56
Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection. Lancet (1993) 1.55
Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol (2000) 1.55
Neurocysticercosis in an Italian traveler to Latin America. Am J Trop Med Hyg (1999) 1.53
Special factors in biological strings. J Theor Biol (2000) 1.51
Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study Group. Clin Infect Dis (1995) 1.51
Stenting of the arterial duct in newborns with duct-dependent pulmonary circulation. Heart (2007) 1.51
Decreased sympathetic inhibition in gastroesophageal reflux disease. Clin Auton Res (2001) 1.49
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS (1995) 1.47
Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. J Infect Dis (1997) 1.47
Aortic valve replacement for aortic stenosis in persons aged 80 years and over. Am J Cardiol (1991) 1.46
Parenteral and sexual transmission of human immunodeficiency virus in intravenous drug users: a study of seroconversion. The Northern Italian Seronegative Drug Addicts (NISDA) Study. Am J Epidemiol (1992) 1.46
p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res (1994) 1.46
Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Dig Liver Dis (2001) 1.46
Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr (2000) 1.46
The role of EGF-related peptides in tumor growth. Front Biosci (2001) 1.45
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media. J Clin Microbiol (1998) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS (2001) 1.41
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41
Virological treatment failure of highly active antiretroviral therapy in an unselected cohort of HIV-infected patients. AIDS (1998) 1.40
Histidine supplements in the treatment of uraemic anaemia. Proc Eur Dial Transplant Assoc (1973) 1.40
Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood (1998) 1.39
Does HHV-8 have a protective role on the development of HIV encephalopathy? Italian HIV-Seroconversion Study. Neurology (1999) 1.38
A simple scoring system to assess risk of hematological side effects in zidovudine recipients. AIDS (1991) 1.38
Epidemic Kaposi's sarcoma in Italy, a country with intravenous drug abusers as the major group at risk for AIDS: report of 60 cases. AIDS (1989) 1.38
An imported case of acute pulmonary coccidioidomycosis in an Italian traveller. Infection (2014) 1.38
Nested polymerase chain reaction for diagnosis and monitoring treatment response in AIDS patients with tuberculous meningitis. AIDS (1995) 1.37
Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome. Clin Exp Immunol (1986) 1.37
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses (1997) 1.36
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis (2012) 1.36
SQUID-based microwave cavity search for dark-matter axions. Phys Rev Lett (2010) 1.36
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr (1999) 1.35
Malaria and anaemia in pregnant women in urban Zanzibar, Tanzania. Ann Trop Med Parasitol (1994) 1.34
Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr (2000) 1.31
HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection. Lancet (1986) 1.31
Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology (1997) 1.31
Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr (2001) 1.31
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol (2011) 1.30
Treatment and serological studies of an Italian case of penicilliosis marneffei contracted in Thailand by a drug addict infected with the human immunodeficiency virus. Eur J Epidemiol (1993) 1.30